Salvinorin A is known as a highly selective kappa opioid receptor agonist with antinociceptive but mostly pro-depressive effects.
Aims:
In this article, we present its new semisynthetic analog with preferential mu opioid affinity, and promising antinociceptive, as well as antidepressant-like activities.
Methods:
Competitive binding studies were performed for salvindolin with kappa opioid and mu opioid. The mouse model of nociception (acetic-acid-induced writhing, formalin, and hot plate tests), depression (forced swim and tail suspension tests), and the open field test, were used to evaluate antinociceptive, antidepressant-like, and locomotion effects, respectively, of salvindolin. We built a 3-D molecular model of the kappa opioid receptor, using a mu opioid X-ray crystal structure as a template, and docked salvindolin into the two proteins.
Results/outcomes:
Salvindolin showed affinity towards kappa opioid and mu opioid receptors but with 100-fold mu opioid preference. Tests of salvindolin in mice revealed good oral bioavailability, antinociceptive, and antidepressive-like effects, without locomotor incoordination. Docking of salvindolin showed strong interactions with the mu opioid receptor which matched well with experimental binding data. Salvindolin-induced behavioral changes in the hot plate and forced swim tests were attenuated by naloxone (nonselective opioid receptor antagonist) and/or naloxonazine (selective mu opioid receptor antagonist) but not by nor-binaltorphimine (selective kappa opioid receptor antagonist). In addition, WAY100635 (a selective serotonin 1A receptor antagonist) blocked the antidepressant-like effect of salvindolin.
Conclusions/interpretation:
By simple chemical modification, we were able to modulate the pharmacological profile of salvinorin A, a highly selective kappa opioid receptor agonist, to salvindolin, a ligand with preferential mu opioid receptor affinity and activity on the serotonin 1A receptor. With its significant antinociceptive and antidepressive-like activities, salvindolin has the potential to be an analgesic and/or antidepressant drug candidate.
AvielloGBorrelliFGuidaFet al. (2011) Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo. J Mol Med89: 891–902.
2.
BarrotM (2012) Tests and models of nociception and pain in rodents. Neuroscience211: 39–50.
3.
BerrocosoEIkedaKSoraIet al. (2013) Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol16: 151–162.
4.
BerrocosoESanchez-BlazquezPGarzonJet al. (2009) Opiates as antidepressants. Curr Pharm Des15: 1612–1622.
5.
BrocardoPSBudniJLobatoKRet al. (2009) Evidence for the involvement of the opioid system in the antidepressant-like effect of folic acid in the mouse forced swim test. Behav Brain Res200: 122-127.
6.
CahillCMWalwynWTaylorAMWet al. (2016) Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol Sci37: 963–976.
7.
CarlezonWAJrBeguinCDiNieriJAet al. (2006) Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther316: 440–447.
8.
ChavkinCSudSJinWet al. (2004) Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: Structural and functional considerations. J Pharmacol Exp Ther308: 1197–1203.
9.
CheTMajumdarSZaidiSAet al. (2018) Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell172: 55–67.
10.
ChilmonczykZBojarskiAJPilcAet al. (2015) Functional selectivity and antidepressant activity of serotonin 1A receptor ligands. Hashimoto K, ed. Int J Mol Sci16: 18474–18506.
11.
CostaEALinoRCGomesMNet al. (2013) Anti-inflammatory and antinociceptive activities of LQFM002 - A 4-nerolidylcatechol derivative. Life Sci92: 237–244.
12.
CryanJFMombereauCVassoutA (2005) The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev29: 571–625.
13.
CunninghamCWRothmanRBPrisinzanoTE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev63: 316–347.
14.
DumanRS (2018) Ketamine and rapid-acting antidepressants: A new era in the battle against depression and suicide. F1000Research7: 100–659.
15.
FajemiroyeJOGaldinoPMFlorentinoIFet al. (2014) Plurality of anxiety and depression alteration mechanism by oleanolic acid. J Psychopharm28: 923–934.
FajemiroyeJOPolepallyPRda CunhaLCet al. (2017) 22-Azidosalvinorin A exhibits antidepressant-like effect in mice. Eur J Pharmacol800: 96–106.
18.
FernandezMColodro-CondeLHartvigsenJet al. (2017) Chronic low back pain and the risk of depression or anxiety symptoms: Insights from a longitudinal twin study. Spine J17: 905–912.
19.
FriesnerRAMurphyRBRepaskyMPet al. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein - ligand complexes. J Med Chem49: 6177–6196.
20.
GassawayMMRivesMLKruegelACet al. (2014) The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist. Transl Psychiatry4: e411.
21.
GroerCETidgewellKMoyerRAet al. (2007) An opioid agonist that does not induce μ-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol71: 549–557.
22.
GuentherUManzkeTWriggeHet al. (2009) The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situand in vivo. Anesth Analg108: 1169–1176.
GunnABobeckENWeberCet al. (2011) The influence of non-nociceptive factors on hot plate latency in rats. J Pain12: 222–227.
25.
HalgrenTAMurphyRBFriesnerRAet al. (2004) Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem47: 1750–1759.
26.
HarderEDammWMapleJet al. (2016) OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theor Comput12: 281–296.
27.
HardingWWTidgewellKByrdNet al. (2005b) Neoclerodane diterpens as a novel scaffold for μ-opioid receptor ligands. J Med Chem48: 4765–4771.
28.
HardingWWTidgewellKSchmidtMet al. (2005a) Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett7: 3017–3020.
KenefickAL (2004) Pain treatment and quality of life: Reducing depression and improving cognitive impairment. J Gerontol Nurs30: 22–29.
35.
KivellBMEwaldAWPrisinzanoTE (2014) Salvinorin A analogs and other kappa opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol69: 481–511.
36.
KleiberBJainSTrivediMH (2005) Depression and pain: Implications for symptomatic presentation and pharmacological treatments. Psychiatr2: 12–18.
KumarihamyMLeonFPettawaySet al. (2015) In vitro opioid receptor affinity and in vivo behavioral studies of Nelumbo nucifera flower. J Ethnopharmacol174: 57–65.
39.
LeBDGozariuMCaddenSW (2001) Animals models of nociception. Pharmacol Rev53: 597–652.
40.
LeeDYWKarnatiVVRHeMet al. (2005) Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett15: 3744–3747.
41.
LeonFGaoJDaleORet al. (2013) Secondary metabolites from Eupenicillium parvum and their in Vitro binding affinity for human opioid and cannabinoid receptors. Planta Med79: 1756–1761.
MaloneMH (1983) The pharmacological evaluation of natural products: General and specific approaches to screening ethnopharmaceuticals. J Ethnopharmacol8: 127–147.
44.
ManglikAKruseACKobilkaTSet al. (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature485: 321–326.
45.
McCurdyCRSufkaKJSmithGHet al. (2006) Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav83: 109–113.
46.
MoserVC (2011) Functional assays for neurotoxicity testing. Toxicol Pathol39: 36–45.
47.
MowryMMosherMBrinerW (2003) Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs35: 379–382.
48.
OliveiraLPSilvaDPBFlorentinoIFet al. (2017) New pyrazole derivative 5-[1-(4-fluorophenyl)-1H-pyrazol-4-yl]-2H-tetrazole: Synthesis and assessment of some biological activities. Chem Biol Drug Des89: 124–135.
49.
PatonKFKumarNCrowleyRSet al. (2017) The analgesic and anti-inflammatory effects of Salvinorin A analog β-tetrahydropyran Salvinorin B in mice. Eur J Pain21: 1039–1050.
50.
PeciñaMKarpJFMathewSet al. (2018) Endogenous opioid system dysregulation in depression: Implications for new therapeutic approaches. Mol Psychiatry. Epub ahead of print 28 June 2018. DOI: 10.1038/s41380-018-0117-2.
51.
PennETracyDK (2012) The drugs don’t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol2: 179–188.
52.
PolepallyPRHubenKVardyEet al. (2014) Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor. Eur J Med Chem85: 818–829.
53.
PorsoltRDLe PichonMJalfreM (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature266: 730–732.
54.
PrisinzanoTERothmanRB (2008) Salvinorin A analogs as probes in opioid pharmacology. Chem Rev108: 1732–1743.
55.
RenJDingXGreerJJ (2015) 5-HT1A receptor agonist Befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats. Anesthesiology122: 424–434.
56.
RenardCEDaillyEDDenisJPet al. (2003) Monoamine metabolism changes following the mouse forced swim test but not the tail suspension test. Fund Clin Pharmacol17: 449–455.
57.
Rojas-CorralesMOBerrocosoEGibert-RaholaJet al. (2002) Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci72: 143–152.
SalagaMPolepallyPRSobczakMet al. (2014a) Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J Pharmacol Exp Ther350: 69–78.
60.
SalagaMPolepallyPRZakrzewskiPKet al. (2014b) Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors. Biochem Pharmacol92: 618–626.
61.
SalagaMPolepallyPRZielinskaMet al. (2015) Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice. Brit J Pharmacol172: 4331–4341.
62.
SamuelsBANautiyalKMKruegelACet al. (2017) The behavioral effects of the antidepressant Tianeptine require the mu-opioid receptor. Neuropsychopharmacology42: 2052–2063.
63.
SanguinettiMCTristani-FirouziM (2006) hERG potassium channels and cardiac arrhythmia. Nature440: 463–469.
64.
SavageSRKirshKLPassikSD (2008) Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract4: 4–25.
65.
SawynokJEsserMJReidAR (2001) Antidepressants as analgesics: An overview of central and peripheral mechanisms of action. J Psychiatr Neurosci26: 21–29.
66.
Schrödinger Release 2016-1: Glide, Schrödinger, LLC, New York, NY, 2016.
67.
Schrödinger Release 2016-1: LigPrep, Schrödinger, LLC, New York, NY, 2016.
68.
Schrödinger Release 2016-1: Maestro, Schrödinger, LLC, New York, NY, 2016.
69.
Schrödinger Release 2016-1: Prime, Schrödinger, LLC, New York, NY, 2016.
70.
Schrödinger Release 2016-1: QikProp, Schrödinger, LLC, New York, NY, 2016.
71.
StollALRueterS (1999) Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry156: 2017.
72.
SteruLChermatRThierryBet al. (1985) The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology85: 367–370.
73.
StraubW (1911) Eine empfindliche biologische Reaktion auf Morphin. Dtsch Med Wochenschr37: 1462.
74.
TaoLZhangPQinCet al. (2015) Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools. Ad Drug Deliver Rev86: 83–100.
75.
TidgewellKHardingWWSchmidtMet al. (2004) A facile method for the preparation of deuterium labeled salvinorin A: Synthesis of [2,2,2,- 2H3]-salvinorin A. Bioorg Med Chem Lett14: 5099–5051.
76.
TidgewellKGroerCEHardingWWet al. (2008) Herkinorin analogues with differential β-arrestin-2 interactions. J Med Chem51: 2421–2431.
77.
VardyEMosierPDFrankowskiKJet al. (2013) Chemotype-selective modes of action of κ-opioid receptor agonists. J Biol Chem288: 34470–34483.
78.
WangYTangKInanSet al. (2005) Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther312: 220–230.
79.
WangYXingJXuYet al. (2015) In silico ADME/T modeling for rational drug design. Q Rev Biophys48: 488–515.
80.
WoolfeGMacDonaldAD (1944) The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther80: 300–307.
81.
WuHWackerDMileniMet al. (2012) Structure of the human κ-opioid receptor in complex with JDTic. Nature485: 327–332.
82.
XinJZhangYHeZet al. (2016) Highly selective non-opioid kappa opioid receptor (KOR) agonist salvinorin A protects against forebrain ischemia-induced brain injury in rats. Brain Res1637: 168–176.
83.
YanFMosierPDWestkaemperRBet al. (2005) Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to κ-opioid receptors. Biochemistry44: 8643–8651.
84.
YinZ-YLiLChuS-Set al. (2016) Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep6: 27129.
85.
YuanSPalczewskiKPengQet al. (2015) The mechanism of ligand-induced activation or inhibition of μ-and κ-opioid receptors. Angew Chem Int Ed Engl54: 7560–7563.
86.
YuanSVogelHFilipekS (2013) The role of water and sodium ions in the activation of the mu-opioid receptor. Angew Chem Int Ed Engl52: 10112–10115.
87.
ZarrindastMRAlaei-NiaKShafizadehM (2001) On the mechanism of tolerance to morphine-induced Straub tail reaction in mice. Pharmacol Biochem Behav69: 419–424.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
